Home Featured Page 3

Featured

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

William Leonard Pickard participating in celebration for Sasha Shulgin’s new book ‘The Nature of Drugs’

PTSF49 – MDMA For Alcoholism, The Placebo Effect, and Ceremonial Magicians

Can Psilocybin Assisted Psychotherapy Change Attachment Style?

CB Therapeutics Closes on Oversubscribed Series A

COMPASS Pathways expands its Discovery Center through new collaborations with world-leading...

Champignon Brands Announces Filing of Listing Statement

Psychedelic Bulletin: DMT for Stroke; MindMed’s Drug Discovery Partnership; Psychedelics are...

Former Vancouver Firefighter Declares Psychedelic Drug Saved His Life

Psychedelic Research Bulletin: March 2021

Catching Up with the Psychedelic Entourage Effect: Part 3 – Field...

Psychedelics Research Review: January 2021

1 234...292 Page 3 of 292

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on...

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

William Leonard Pickard participating in celebration for Sasha Shulgin’s new book ‘The Nature of Drugs’

PTSF49 – MDMA For Alcoholism, The Placebo Effect, and Ceremonial Magicians

Interview With Ronan Levy

Can Psilocybin Assisted Psychotherapy Change Attachment Style?

CB Therapeutics Closes on Oversubscribed Series A

COMPASS Pathways expands its Discovery Center through new collaborations with world-leading...

Champignon Brands Announces Filing of Listing Statement

Psychedelic Bulletin: DMT for Stroke; MindMed’s Drug Discovery Partnership; Psychedelics are...

Former Vancouver Firefighter Declares Psychedelic Drug Saved His Life

Psychedelic Research Bulletin: March 2021

Catching Up with the Psychedelic Entourage Effect: Part 3 – Field...

Psychedelics Research Review: January 2021

EDITOR PICKS

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on...

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY